Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 4 records in total 4
    records per page

    Characteristics and Prognosis of COVID-19 in Patients with COPD MESHD

    Authors: Desirée Graziani; Joan B Soriano; Carlos Del Rio-Bermudez; Diego Morena; Teresa Díaz; María Castillo; Miguel Alonso; Julio Ancochea; José Luis Izquierdo

    id:10.20944/preprints202009.0242.v1 Date: 2020-09-11 Source:

    Patients with COPD MESHD have a higher prevalence SERO of coronary ischemia MESHD and other factors that put them at risk for COVID-19-related complications. We aimed to explore the impact of COVID-19 in a large population-based sample of patients with COPD MESHD in Castilla-La Mancha MESHD, Spain. We analyzed clinical data in electronic health records from January 1st to May 10th, 2020 by using Natural Language Processing through the SAVANA Manager® clinical platform. Out of 31,633 COPD MESHD patients, 793 had a diagnosis of COVID-19. The proportion of patients with COVID-19 in the COPD population (2,51%; CI95% 2,33 – 2,68) was significantly higher than in the general population aged TRANS > 40 years (1,16%; 95%CI 1,14 – 1,18); P < .001. Compared with COPD-free individuals, COPD MESHD patients with COVID-19 showed significantly poorer disease prognosis, as evaluated by hospitalizations (31,1 % vs 39,8%: OR 1,57; 95%CI 1,14 – 1,18) and mortality (3,4% vs 9,3%: OR 2,93; 95%CI 2,27 – 3,79). Patients with COPD MESHD and COVID-19 were significantly older (75 vs. 66 years), predominantly male TRANS (83% vs 17%), smoked more frequently, and had more comorbidities than their non-COPD counterparts. Pneumonia HP was the most common diagnosis among COPD MESHD patients hospitalized due to COVID-19 (59%); 19% of patients showed pulmonary infiltrates HP suggestive of pneumonia HP pneumonia MESHD and heart failure MESHD. Mortality in COPD MESHD patients with COVID-19 was associated with older age TRANS and prevalence SERO of heart failure MESHD (P<0.05). COPD MESHD patients with COVID-19 showed higher rates of hospitalization and mortality, mainly associated with pneumonia HP pneumonia MESHD. This clinical profile is different from exacerbations caused by other respiratory viruses in the winter season.

    Initial experience in Mexico with convalescent plasma SERO in COVID-19 patients with severe respiratory failure HP respiratory failure MESHD, a retrospective case series

    Authors: Michel F. Martinez-Resendez; Fernando Castilleja-Leal; Alejandro Torres-Quintanilla; Augusto Rojas-Martinez; Gerardo Garcia-Rivas; Rocio Ortiz-Lopez; Victor Trevino; Reynaldo Lara-Medrano; Hiram Villanueva-Lozano; Teresa Ramirez-Elizondo; Victor Sanchez-Nava; Francisco Moreno-Hoyos; Alfonso Martinez-Thomae; Martin Hernandez-Torre; Carlos Diaz-Olachea; Servando Cardona-Huerta; Sylvia de la Rosa-Pacheco; Carlos Diaz-Garza; Paola Reynoso-Lobo; Alma R. Marroquin-Escamilla; Jessica G. Herrera-Gamboa; Fatima M. Alvarado-Monroy; Claudia D. Aguayo-Millan; Francisco F. Villegas-Macedo; Jesus E. Flores-Osorio; Daniel Davila-Gonzalez; Maria E. Diaz-Sanchez; Guillermo Torre-Amione

    doi:10.1101/2020.07.14.20144469 Date: 2020-07-20 Source: medRxiv

    Introduction: Hospital mortality due to COVID-19 in Mexico is high (32%) and as of today, effective treatment options are limited. More effective treatments that shorten hospital stay and reduce mortality are needed. Initial reports for the use of convalescent plasma SERO (CP) therapy for COVID-19 appear promising. We describe a case series of eight patients with impending respiratory failure HP respiratory failure MESHD, who underwent CP therapy. Methods: Six male TRANS and two female TRANS ( ages TRANS 31 to 79) patients that were admitted to the intensive-care unit for severe COVID-19 were transfused with two doses of CP (250 mL per dose, anti-SARS-CoV-2 IgG titers > 1:100). Donors were six SARS-CoV-2 infected MESHD males TRANS who remained asymptomatic TRANS for > 7 days and were negative for two nasopharyngeal RT-PCR tests. Clinical characteristics, inflammatory and cellular injury markers, chest X-ray findings and viral loads were analyzed before and after CP administration. Viral load association to disease severity was further analyzed on a separate cohort of asymptomatic TRANS vs hospitalized patients with COVID-19. Results: Eight patients with respiratory failure HP respiratory failure MESHD were successfully discharged with a median length of stay of 22.5 (IQR 18.25-29.00). After CP therapy, we observed a reduction of C-reactive protein (CRP) (median, 22.80 mg/dL vs. 1.63 mg/dL), and of procalcitonin (median, 0.27 ng/mL vs. 0.13 ng/mL). High- Sensitivity SERO Cardiac Troponin I (hs-cTnI), Brain Natriuretic Peptide (BNP) and Lactate Dehydrogenase (LDH) were lower, and a mild reduction of pulmonary infiltrates HP by chest X-ray was observed. Lastly, a reduction of viral load was after CP therapy was found. (log, median [IQR], 1.2 [0.70-2.20] vs. 0.25 [0.00-1.78]). We observed no adverse effects. Conclusions: CP could potentially be an effective therapeutic option for patients with severe COVID-19. Clinical benefit needs to be studied further through randomized controlled trials.


    Authors: Antoni Sisó-Almirall; Belchin Kostov; Minerva Mas-Heredia; Sergi Vilanova-Rotllan; Ethel Sequeira-Aymar; Mireia Sans-Corrales; Elisenda Sant-Arderiu; Laia Cayuelas-Redondo; Angela Martínez-Pérez; Noemí García Plana; August Anguita-Guimet; Jaume Benavent-Àreu

    doi:10.1101/2020.06.18.20134510 Date: 2020-06-20 Source: medRxiv

    Background In addition to the lack of COVID-19 diagnostic tests for the whole Spanish population, the current strategy is to identify the disease early to limit contagion in the community. Aim To determine clinical factors of a poor prognosis in patients with COVID-19 infection MESHD. Design and Setting Descriptive, observational, retrospective study in three primary healthcare centres with an assigned population of 100,000. Method Examination of the medical records of patients with COVID-19 infections confirmed TRANS by polymerase chain reaction. Results We included 322 patients (mean age TRANS 56.7 years, 50% female TRANS, 115 (35.7%) aged TRANS [≥] 65 years). The best predictors of ICU admission or death MESHD were greater age TRANS, male TRANS sex (OR=2.99; 95%CI=1.55 to 6.01), fever HP fever MESHD (OR=2.18; 95%CI=1.06 to 4.80), dyspnoea MESHD (OR=2.22; 95%CI=1.14 to 4.24), low oxygen saturation (OR=2.94; 95%CI=1.34 to 6.42), auscultatory alterations (OR=2.21; 95%CI=1.00 to 5.29), heart disease MESHD (OR=4.37; 95%CI=1.68 to 11.13), autoimmune disease MESHD (OR=4.03; 95%CI=1.41 to 11.10), diabetes MESHD (OR=4.00; 95%CI=1.89 to 8.36), hypertension HP hypertension MESHD (OR=3.92; 95%CI=2.07 to 7.53), bilateral pulmonary infiltrates HP (OR=3.56; 95%CI=1.70 to 7.96), elevated lactate-dehydrogenase (OR=3.02; 95%CI=1.30 to 7.68), elevated C-reactive protein (OR=2.94; 95%CI=1.47 to 5.97), elevated D-dimer (OR=2.66; 95%CI=1.15 to 6.51) and low platelet count (OR=2.41; 95%CI=1.12 to 5.14). Myalgia HP Myalgia MESHD or artralgia (OR=0.28; 95%CI=0.10 to 0.66), dysgeusia MESHD (OR=0.28; 95%CI=0.05 to 0.92) and anosmia HP anosmia MESHD (OR=0.23; 95%CI=0.04 to 0.75) were protective factors. Conclusion Determining the clinical, biological and radiological characteristics of patients with suspected COVID-19 infection MESHD will be key to early treatment and isolation and the tracing of contacts TRANS.

    Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China.

    Authors: Dawei Wang; Yimei Yin; Chang Hu; Xing Liu; Xingguo Zhang; Shuliang Zhou; Mingzhi Jian; Haibo Xu; John Prowle; Bo Hu; Yirong Li; Zhi-Yong Peng

    doi:10.21203/ Date: 2020-03-04 Source: ResearchSquare

    Background In December 2019, Coronavirus Disease MESHD 2019 (COVID-19) outbreak was reported from Wuhan, China. Information on the clinical course and prognosis of COVID-19 was not thoroughly described. We described the clinical courses and prognosis in COVID-19 patients. Methods Retrospective case series of COVID-19 patients from Zhongnan Hospital of Wuhan University in Wuhan, and Xi-shui Hospital, Hubei Province, China, up to February 10, 2020. Epidemiological, demographic and clinical data were collected. Clinical course of survivors and non-survivors were compared. Risk factors for death MESHD were analyzed. Results A total of 107 discharged patients with COVID-19 were enrolled. The clinical course of COVID-19 presented as a tri-phasic pattern. Week 1 after illness onset was characterized by fever HP fever MESHD, cough HP cough MESHD, dyspnea HP dyspnea MESHD, lymphopenia HP lymphopenia MESHD and radiological multilobar pulmonary infiltrates HP. In severe cases, thrombocytopenia HP thrombocytopenia MESHD, acute kidney injury HP acute kidney injury MESHD, acute myocardial injury MESHD or adult TRANS adult MESHD respiratory distress HP syndrome were observed. During week 2, in mild cases, fever HP fever MESHD, cough HP cough MESHD and systemic symptoms began to resolve and platelet count rose to normal range, but lymphopenia HP lymphopenia MESHD persisted. In severe cases, leukocytosis HP leukocytosis MESHD, neutrophilia HP and deteriorating multi-organ dysfunction were dominant. By week 3, mild cases had clinically resolved except for lymphopenia HP lymphopenia MESHD. However, severe cases showed persistent lymphopenia HP lymphopenia MESHD, severe acute respiratory dyspnea syndrome MESHD dyspnea HP syndrome , refractory shock MESHD shock HP, anuric acute kidney injury MESHD acute kidney injury HP, coagulopathy MESHD, thrombocytopenia HP thrombocytopenia MESHD and death MESHD. Older age TRANS and male TRANS sex were independent risk factors for poor outcome of the illness. Conclusions A period of 7–13 days after illness onset is the critical stage in COVID-19 course. Age TRANS and male TRANS gender TRANS were independent risk factors for death of COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.